+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of statin treatment in patients with acute myocardial infarction and left ventricular systolic dysfunction according to the level of high-sensitivity C-reactive protein



Effect of statin treatment in patients with acute myocardial infarction and left ventricular systolic dysfunction according to the level of high-sensitivity C-reactive protein



International Heart Journal 55(2): 106-112



The effects of statins on the prognosis of patients with left ventricular (LV) systolic dysfunction remain controversial. The aim of this study was to assess the effect of statin treatment on clinical outcomes in acute myocardial infarction (AMI) patients with LV systolic dysfunction. A total of 5,119 AMI patients with LV ejection fraction less than 50% on the initial echocardiogram were analyzed in the Korean Acute Myocardial Infarction Registry. The study population was divided into 4 groups according to the level of high sensitivity C-reactive protein (hs-CRP) and statin treatment: low hs-CRP (hs-CRP ≤ 2.0 mg/L) and high hs-CRP (hs-CRP > 2 mg/L) with or without statin therapy. We evaluated the incidence of major adverse cardiac events (MACEs) including cardiac death, reinfarction, target lesion revascularization, and coronary artery bypass grafting during a 12-month period in each group. Statin therapy did not significantly prevent the MACEs in the low hs-CRP groups (with statin: 10.1% versus without statin: 12.0%, P = 0.249). In the high hs-CRP groups, however, the incidence of MACEs was significantly decreased with statin treatment (with statin: 11.3%, without statin: 20.8%, P < 0.001). These findings were consistently observed in all subgroups of the high-hs CRP group, including the subgroup with an LV ejection fraction less than 40%. In a multivariable logistic regression analysis of the high hs-CRP group, lack of statin therapy was a significant predictor of MACE incidence (odds ratio: 1.573, 95% confidence interval: 1.079-2.293, P = 0.018). The statin treatment was associated with better outcome in AMI and LV dysfunction patients with hs-CRP ≥ 2 mg/dL.

(PDF emailed within 1 workday: $29.90)

Accession: 052829657

Download citation: RISBibTeXText

PMID: 24632965


Related references

Statin treatment in patients with acute myocardial infarction according to left ventricular systolic function. Atherosclerosis 241(1): E198-E199, 2015

High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart and Vessels 18(2): 67-74, 2003

Predictive value of the serum level of N-terminal pro-brain natriuretic peptide and high-sensitivity C-reactive protein in left ventricular remodeling after acute myocardial infarction. Journal of Clinical Laboratory Analysis 20(1): 19-22, 2006

Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112(22): 3391-3399, 2005

Beneficial effects of statin treatment on coronary microvascular dysfunction and left ventricular remodeling in patients with acute myocardial infarction. International Journal of Cardiology 155(3): 442-447, 2012

Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. Journal of Cardiology 2019, 2019

Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. International Journal of Cardiology 167(5): 1848-1853, 2014

Eplerenone attenuates left ventricular remodeling after acute myocardial infarction in patients with left ventricular Systolic dysfunction. 2007

Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study. European Heart Journal 34(Suppl 1): P3293-P3293, 2013

Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. Journal of the Renin-Angiotensin-Aldosterone System 17(4), 2017

Concomitant impact of high-sensitivity C-reactive protein and renal dysfunction in patients with acute myocardial infarction. Yonsei Medical Journal 55(1): 132-140, 2014

Autonomic dysfunction and new-onset atrial fibrillation in patients with left ventricular systolic dysfunction after acute myocardial infarction: a CARISMA substudy. Journal of Cardiovascular Electrophysiology 21(9): 983-990, 2011

The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?. European Journal of Heart Failure 4(4): 501-506, 2002

The relationship between high sensitivity C-reactive protein level at admission and myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 34(5): 422-424, 2006

Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology 130(3): 457-462, 2008